Table 4.
Association between severity of 12-month DSM-IV/CIDI disorders and days out of role in the WMH surveys
| Serious | Moderate | Mild | Wald F1 | (p-value) | ||||
|---|---|---|---|---|---|---|---|---|
| Mean | (se) | Mean | (se) | Mean | (se) | |||
| I. WHO Region: Pan American Health Organization (PAHO) | ||||||||
| Colombia | 53.0 | (8.9) | 33.7 | (6.7) | 15.6 | (3.0) | 10.8* | (<.001) |
| Mexico | 42.8 | (6.9) | 26.3 | (5.3) | 11.7 | (2.7) | 11.7* | (<.001) |
| United States | 135.9 | (6.9) | 65.3 | (4.6) | 35.7 | (2.7) | 126.1* | (<.001) |
| II. WHO Region: African Regional Office (AFRO) | ||||||||
| Nigeria | 56.7 | (22.3) | 51.5 | (18.8) | 25.9 | (7.4) | 1.6 | (.20) |
| South Africa | 73.1 | (9.7) | 49.3 | (6.5) | 32.5 | (4.8) | 9.1* | (<.001) |
| III. WHO Region: Eastern Mediterranean Regional Office (EMRO) | ||||||||
| Lebanon | 81.4 | (10.6) | 42.0 | (9.5) | 13.6 | (5.4) | 14.4* | (<.001) |
| IV. WHO Region: European Regional Office (EURO) | ||||||||
| Belgium | 96.1 | (26.0) | 59.9 | (11.6) | 42.5 | (9.6) | 3.7* | (.025) |
| France | 105.7 | (14.3) | 71.8 | (16.5) | 67.6 | (17.3) | 2.7 | (.07) |
| Germany | 77.8 | (18.1) | 33.2 | (8.2) | 45.7 | (12.1) | 2.2 | (.12) |
| Israel | 184.6 | (12.5) | 109.4 | (10.1) | 44.6 | (9.1) | 41.8* | (<.001) |
| Italy | 178.5 | (25.6) | 55.6 | (10.9) | 41.7 | (11.2) | 11.7* | (<.001) |
| Netherlands | 140.7 | (19.9) | 87.1 | (17.1) | 68.9 | (22.7) | 4.0* | (.018) |
| Spain | 131.5 | (15.8) | 56.6 | (10.0) | 57.4 | (22.0) | 8.1* | (<.001) |
| Ukraine | 142.5 | (14.5) | 103.2 | (9.2) | 51.6 | (9.9) | 13.9* | (<.001) |
| V. WHO Region: Western Pacific Regional Office (WPRO) | ||||||||
| People’s Republic of China | 48.7 | (18.4) | 21.1 | (5.2) | 21.3 | (7.2) | 1.5 | (.23) |
| Japan | 51.0 | (17.3) | 39.3 | (10.6) | 22.5 | (6.4) | 3.7* | (.024) |
| New Zealand | 98.1 | (5.9) | 54.6 | (3.4) | 36.4 | (3.6) | 40.7* | (<.001) |
1
No demographic controls were used.
*
Significant association between severity and days out of role at the .05 level.